Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

NCT02023359 · clinicaltrials.gov ↗

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Everolimus and exemestane

Sponsor

Novartis Healthcare A/S